Prevalence of cervical Human Papillomavirus (HPV) infection in Vanuatu

Cancer Prevention Research

Volumn 5, Issue 5, 2012, Pages 746-753

  Aruhuri, Bernadette ^a   Tarivonda, Len ^a   Tenet, Vanessa ^b   Sinha, Rohit ^c   Snijders, Peter J F ^d   Clifford, Gary ^b   Pang, James ^c   McAdam, Margaret ^e   Meijer, Chris J L M ^d   Frazer, Ian H ^c,e   Franceschi, Silvia ^b  

^a Ministry of Health   (Vanuatu)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Australians Helping Abroad   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PACIFIC ISLANDS; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; ADOLESCENT; AGED; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; UTERINE CERVIX; UTERINE CERVIX TUMOR; VANUATU; VIROLOGY;

VIRUS DNA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VANUATU; YOUNG ADULT;

EID: 84866177118     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0515     Document Type: Article

References (25)

1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents. Vol. IX. IARC Scientific Publication No. 160. [IX]. Lyon, France: IARC; 2007.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France, International Agency for Research on Cancer. [cited January 2011]. Available from: http://globocan.iarc.fr; 2010.
3. Garland SM, Brotherton JM, Skinner SR, Pitts M, Saville M, Mola G, et al. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention. Vaccine 2008;26 Suppl 12:M80-8.
4. McAdam M, Sakita J, Tarivonda L, Pang J, Frazer IH. Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. PLoS One 2010;5:e13266.
5. World Health Organization. Weekly epidemiological record: monitoring the coverage and impact of human papillomavirus vaccine - report of WHO meeting, November 2009. Vol. 25. Geneva, Switzerland: WHO; 2010. p. 237-48.
6. National Health and Medical Research Council (NHMRC). Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra, Australia: NHMRC; 2005. p. 19-23.
7. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-speci fi c curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84. (Pubitemid 44691325)
8. Keita N, Clifford GM,Koulibaly M, Douno K, Kabba I,Haba M, et al.HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009;101:202-8.
9. Roda Husman AM, Snijders PJ, Stel HV, van den Brule AJ, Meijer CJ, Walboomers JM. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 1995;72:412-7.
10. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-7. (Pubitemid 30434349)
11. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6 +PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-87. (Pubitemid 34208623)
12. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008;68:8813-24.
13. Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, et al. Human papillomavirus prevalence amongst Indigenous and non-Indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011;9:104.
14. Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, Avirmed D, et al. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev 2008;17:1731-8.
15. Maucort-Boulch D, Franceschi S, Plummer M. International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev 2008;17:717-20. (Pubitemid 351469225)
16. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9. (Pubitemid 46962343)
17. Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJF, Clifford GM, et al. Sexual behavior, condom use, and HPV: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2006;15:326-33. (Pubitemid 43342183)
18. Vaccarella S, Herrero R, Snijders PJ, Dai M, Thomas JO, Hieu NT, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008;37:536-46. (Pubitemid 351804006)
19. Vaccarella S, Herrero R, Dai M, Snijders PJF, Meijer CJLM, Thomas JO, et al. Reproductive factors, oral contraceptive use and HPV infection: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2006;15:2148-53. (Pubitemid 44877039)
20. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009;45:2632-9.
21. Gage JC, Ajenifuja KO, Wentzensen NA, AdepitiAC, Eklund C, Reilly M, et al. The age-speci fi c prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer 2012;130:2111-7.
22. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370:398-406. (Pubitemid 47176655)
23. Li N, Shi JF, Franceschi S, Zhang WH, Dai M, Liu B, et al. Different cervical cancer screening approaches in a Chinese multicentre study. Br J Cancer 2009;100:532-7.
24. Bulkmans N, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke A, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72. (Pubitemid 350137476)
25. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97. (Pubitemid 47598401)